[go: up one dir, main page]

EA202192738A1 - Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos - Google Patents

Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos

Info

Publication number
EA202192738A1
EA202192738A1 EA202192738A EA202192738A EA202192738A1 EA 202192738 A1 EA202192738 A1 EA 202192738A1 EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A1 EA202192738 A1 EA 202192738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
aiolos
ikaros
tricyclic compounds
compounds providing
Prior art date
Application number
EA202192738A
Other languages
English (en)
Inventor
Джэймс А. Хендерсон
Миньшэн Хэ
Эндрю Чарльз Гуд
Эндрю Дж. Филиппс
Original Assignee
С4 Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by С4 Терапьютикс, Инк. filed Critical С4 Терапьютикс, Инк.
Publication of EA202192738A1 publication Critical patent/EA202192738A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны трициклические связывающие цереблон молекулы для разрушения белка Ikaros или белка Aiolos посредством убиквитин-протеасомного пути для терапевтических применений.
EA202192738A 2019-04-12 2020-04-10 Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos EA202192738A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833107P 2019-04-12 2019-04-12
PCT/US2020/027678 WO2020210630A1 (en) 2019-04-12 2020-04-10 Tricyclic degraders of ikaros and aiolos

Publications (1)

Publication Number Publication Date
EA202192738A1 true EA202192738A1 (ru) 2022-03-17

Family

ID=72750851

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192738A EA202192738A1 (ru) 2019-04-12 2020-04-10 Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos

Country Status (16)

Country Link
US (2) US11407732B1 (ru)
EP (1) EP3953332A4 (ru)
JP (1) JP7692362B2 (ru)
KR (1) KR20210152515A (ru)
CN (4) CN113677664B (ru)
AU (1) AU2020272978A1 (ru)
BR (1) BR112021019669A2 (ru)
CA (1) CA3130469A1 (ru)
EA (1) EA202192738A1 (ru)
IL (1) IL287116A (ru)
MA (1) MA55628A (ru)
MX (1) MX2021012524A (ru)
PH (1) PH12021500035A1 (ru)
SG (1) SG11202109024YA (ru)
WO (1) WO2020210630A1 (ru)
ZA (1) ZA202106067B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
CN111278815B (zh) 2017-09-04 2024-03-08 C4医药公司 戊二酰亚胺
KR102605291B1 (ko) * 2018-09-07 2023-11-23 메드샤인 디스커버리 아이엔씨. 트리사이클릭 퓨란에 의해 치환된 피페리디온 화합물
IL293999A (en) 2019-12-20 2022-08-01 C4 Therapeutics Inc Isoindolinone and indazole compounds for the degradation of egfr
WO2021168314A1 (en) 2020-02-21 2021-08-26 Plexium, Inc. Quinazolinone compounds and related compounds
WO2021178920A1 (en) 2020-03-05 2021-09-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
IL300373A (en) * 2020-08-07 2023-04-01 C4 Therapeutics Inc Beneficial treatments for disorders mediated by IKAROS or AIOLOS
KR20230107570A (ko) * 2020-10-14 2023-07-17 씨4 테라퓨틱스, 인코포레이티드 표적화 단백질의 분해를 위한 트리시클릭 이종이관능성 화합물
EP4228639A4 (en) * 2020-10-14 2025-01-22 C4 Therapeutics, Inc. TRICYCLIC LIGANDS TO IMPROVE IKZF2 OR IKZF4
JP2023545509A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 医学的療法のための、ネオ基質を分解する三環式化合物
CN117580592A (zh) 2021-05-05 2024-02-20 渤健马萨诸塞州股份有限公司 用于靶向布鲁顿酪氨酸激酶降解的化合物
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
US20250129047A1 (en) 2021-07-04 2025-04-24 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
EP4367113A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
AU2022335547A1 (en) * 2021-08-27 2024-04-04 Hangzhou Glubio Pharmaceutical Co. Ltd. Isoindolinone compound and use thereof
JP7615989B2 (ja) 2021-09-24 2025-01-17 信越化学工業株式会社 アミン化合物、化学増幅レジスト組成物及びパターン形成方法
TW202322799A (zh) * 2021-10-06 2023-06-16 美商Ｃ４醫藥公司 冠狀病毒非結構性蛋白3降解化合物
WO2023061478A1 (zh) * 2021-10-15 2023-04-20 先声再明医药有限公司 三环类化合物
IL314625A (en) * 2022-02-09 2024-09-01 C4 Therapeutics Inc Morphological forms of CFT7455 and methods of making them
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116120261B (zh) * 2022-11-30 2024-01-23 浙大宁波理工学院 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法
WO2024193641A1 (zh) * 2023-03-21 2024-09-26 上海超阳药业有限公司 异吲哚啉衍生物和苯并吲哚衍生物及其应用
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025083594A1 (en) * 2023-10-18 2025-04-24 Northridge Health Group (Hong Kong) Co., Limited Ptpn2/ptp1b degrader and therapeutic method thereof
WO2025097090A1 (en) * 2023-11-02 2025-05-08 Neomorph, Inc. Substituted (piperidin-4-yl)-1,5-naphthyridine and (piperidin-4-yl)quinoline derivatives and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2660806C (en) 2006-08-30 2015-06-16 Celgene Corporation 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
ES2634915T3 (es) 2006-09-26 2017-09-29 Celgene Corporation Derivados de quinazolinona 5-sustituidos como agentes anti-cancerosos
ES2601131T3 (es) 2007-03-20 2017-02-14 Celgene Corporation Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos
MY157495A (en) 2007-09-26 2016-06-15 Celgene Corp 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009139880A1 (en) 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
SG195613A1 (en) 2008-10-29 2013-12-30 Celgene Corp Isoindoline compounds for use in the treatment of cancer
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US20160313300A1 (en) 2013-12-06 2016-10-27 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CN105985282B (zh) * 2015-01-28 2020-12-08 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
RU2730500C2 (ru) 2016-01-14 2020-08-24 Канпу Биофармасьютикалз, Лтд Производное хиназолинона, способ его получения, фармацевтическая композиция и применения
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
RU2731535C1 (ru) 2016-12-16 2020-09-04 Канпу Биофармасьютикалз, Лтд. Комбинация, ее применение и способ лечения
EP3581182B1 (en) 2017-02-13 2021-09-29 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
EP3590924B1 (en) 2017-02-28 2021-10-27 Kangpu Biopharmaceuticals, Ltd. Novel isoindoline derivative, and pharmaceutical composition and application thereof
WO2019014100A1 (en) 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
EP3813834B1 (en) 2018-06-29 2025-03-26 Dana-Farber Cancer Institute, Inc. New crbn modulators
EP3814330A4 (en) 2018-06-29 2022-07-20 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
CA3102217A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Bispecific degraders
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US20220348556A1 (en) 2018-07-06 2022-11-03 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN112261970B (zh) 2018-07-10 2025-02-07 诺华股份有限公司 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途
AU2020336381A1 (en) 2019-08-27 2022-03-03 The Regents Of The University Of Michigan Cereblon E3 ligase inhibitors
EP4077319A1 (en) 2019-12-20 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase degraders and methods of use thereof

Also Published As

Publication number Publication date
AU2020272978A1 (en) 2021-09-16
IL287116A (en) 2021-12-01
CN113677664B (zh) 2025-04-04
CA3130469A1 (en) 2020-10-15
MX2021012524A (es) 2021-11-12
US11407732B1 (en) 2022-08-09
SG11202109024YA (en) 2021-09-29
EP3953332A1 (en) 2022-02-16
JP7692362B2 (ja) 2025-06-13
KR20210152515A (ko) 2021-12-15
WO2020210630A1 (en) 2020-10-15
ZA202106067B (en) 2024-12-18
CN120172959A (zh) 2025-06-20
CN120172960A (zh) 2025-06-20
CN113677664A (zh) 2021-11-19
CN120172958A (zh) 2025-06-20
MA55628A (fr) 2022-02-16
US20230082430A1 (en) 2023-03-16
JP2022527216A (ja) 2022-05-31
BR112021019669A2 (pt) 2021-12-07
PH12021500035A1 (en) 2022-06-06
EP3953332A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
EA201992546A1 (ru) Средства на основе антител к cd33
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA201790288A1 (ru) Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
WO2020010079A3 (en) Anti-steap1 antigen-binding protein
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA201991029A1 (ru) Ингибиторы magl
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
EA201991876A1 (ru) Антитела против фактора d и их применения
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
ATE437185T1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
BR112022000855A2 (pt) Moduladores de nlrp3
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
BR112021014566A2 (pt) Moduladores de gpr35